Exagen INC

Exagen Inc. announced record revenue and test volumes for Q2 2026, alongside a reduced net loss and increased full-year revenue guidance.

Exagen Inc. announced the final voting results from its 2026 annual meeting of stockholders, including the election of two Class I directors and the ratification of its independent auditor.

Exagen Inc. announced record first quarter 2026 revenue of $17.3 million, a 12% increase year-over-year, alongside an improved adjusted EBITDA loss of $2.2 million.

Exagen Inc. announced the resignation of board member Ana Hooker, leading to a reduction in the board's size from eight to seven members.

Exagen Inc. announced preliminary unaudited financial results for 2025, reporting record full-year revenue and a significant increase in year-end cash.

Exagen Inc. announced record third-quarter 2025 revenue of $17.2 million, a 38% increase year-over-year, alongside improved operating and adjusted EBITDA losses.

Exagen Inc. announced a 15.9% increase in revenue for the second quarter of 2026, driven by higher test volumes and an expanded AVISE CTD platform, alongside improved gross margins.

Exagen Inc. reported an 11.7% increase in revenue for the first quarter of 2026, driven by biomarker enhancements and a growing average selling price.

Exagen Inc. announced significant revenue growth and improved operational cash flow in its third-quarter 2025 results, driven by increased test volumes and new biomarker launches, while also securing substantial new financing.

Exagen Inc. reported a 14.2% increase in revenue for the second quarter of 2025, driven by new biomarker launches and higher test volumes, despite experiencing a significant rise in net losses and operating expenses.

Exagen Inc. announces its financial results for the first quarter of 2025, highlighting a 7.5% increase in revenue compared to the same period last year and securing a new term loan facility.

Exagen Inc. reported a 6.8% decrease in revenue for the third quarter of 2024 compared to the same period in 2023, alongside a net loss of $5.0 million.

Exagen Inc. demonstrates revenue growth, margin expansion, and strategic pipeline development in its fiscal year 2024 results, positioning itself for near-term profitability.

Exagen Inc., a diagnostics company specializing in autoimmune diseases, announced a 15.3% increase in revenue for 2023, reaching $52.5 million, primarily attributed to the increased adoption of its flagship AVISE CTD test and improved commercial payor average selling price (ASP).

Bruce C Robertson, a Director of Exagen Inc., received 37,500 shares of common stock on June 9, 2026.

Paul Kim, a Director of Exagen Inc., received 37,500 shares of common stock on June 9, 2026.

Exagen's Chief Financial Officer, Jeffrey G. Black, reported significant acquisitions of restricted stock units, stock options, and common stock through an employee plan.

EXAGEN's President and CEO, John Aballi, received significant equity awards totaling 250,000 units, comprising 150,000 restricted stock units and options for 100,000 shares, aligning his interests with long-term shareholder value.

Exagen Inc. President and CEO John Aballi reported both a tax-related sale and an Employee Stock Purchase Plan acquisition of company common stock.

Exagen Inc.'s President and CEO, John Aballi, sold 11,430 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Exagen Inc. has released its 2026 proxy statement detailing the upcoming annual meeting agenda, director elections, and executive compensation.

Exagen Inc. will hold its annual meeting on June 10, 2025, to elect directors, ratify the appointment of auditors, and vote on executive compensation.

Exagen Inc. will hold its 2025 Annual Meeting of Stockholders on June 10, 2025, to elect directors, ratify the appointment of its accounting firm, and vote on executive compensation matters.

Exagen Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Exagen Inc. will hold its Annual Meeting of Stockholders on June 10, 2024, to elect directors and ratify the appointment of its independent auditor.

Parian Ultreia LP has filed a Schedule 13G, reporting beneficial ownership of 1,292,000 shares, representing 5.3% of Exagen Inc.'s outstanding class of securities.

Jorey Chernett has filed a Schedule 13G reporting beneficial ownership of 2,413,901 shares, representing a 9.9% stake in Exagen Inc.

RTW Investments and Dr. Roderick Wong have reduced their beneficial ownership in Exagen Inc. to 4.9% of common stock, as reported in their latest Schedule 13G amendment.

NMSIC Co-Investment Fund, L.P. and its general partner, Sun Mountain Capital Partners, L.L.C., reported a 6.04% beneficial ownership stake in Exagen Inc. as of December 31, 2025.

Jorey Chernett has reported beneficial ownership of 5.4% of EXAGEN INC.'s common stock, totaling 1,231,438 shares, as of January 30, 2026.

Laurence W. Lytton reported a 1.0% beneficial ownership stake in Exagen Inc., holding 216,840 shares of common stock as of June 30, 2025.